Automated Kidney and Liver Segmentation in MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Study.
Piotr Woznicki, Florian Siedek, Maatje D A van Gastel...
https://pubmed.ncbi.nlm.nih.gov/36591351/Actively Recruiting
Led by University of Cologne · Updated on 2026-04-30
2000
Participants Needed
12
Research Sites
N/A
Total Duration
Researchers are observing patients with Autosomal Dominant Polycystic Kidney Disease ADPKD to study the management and treatment patterns involving tolvaptan. This multicenter registry collects real-world data from patients who are being evaluated for tolvaptan treatment, are planned to start it, or are already receiving it. The study aims to understand drug dosing, titration, urine osmolarity, treatment duration, and discontinuation rates over a ten-year period. Participants include ADPKD patients from various centers, including nephrology practices and a self-help group network. At enrollment, detailed clinical, laboratory, and imaging data such as MRI and ultrasound are gathered. Patients document their tolvaptan dose and side effects in diaries, and complete yearly questionnaires and quality of life assessments. Data capture occurs annually, reflecting biochemical and imaging findings, medication dosing, adverse events, hospital admissions, and kidney-related complications. During the study, participants are regularly seen approximately once a year without additional trial-specific visits. The registry collects clinical information such as demographics, family history, genotype, co-morbidities, medications, blood pressure, and complications. Laboratory tests include kidney function and urine measurements, while imaging studies focus on kidney volume. Safety and effectiveness are monitored via patient diaries and questionnaires, with data collected continuously for up to ten years to assess long-term treatment patterns and outcomes.
CONDITIONS
The German ADPKD Tolvaptan Treatment Registry
R
Roman-Ulrich Mueller, MD
C
Cornelia Boehme
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Cologne
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 10 years
Participants who undergo routine care for ADPKD are observed. Clinical, laboratory, and imaging data collected during regular care are recorded in the registry to monitor disease progression and treatment effects.
Approximately 1 visit per year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Piotr Woznicki, Florian Siedek, Maatje D A van Gastel...
https://pubmed.ncbi.nlm.nih.gov/36591351/Martijn H van Heugten, Charles J Blijdorp, Sita Arjune...
https://pubmed.ncbi.nlm.nih.gov/38073039/Thomas Bais, Martine G E Knol, Laixi Xue...
https://pubmed.ncbi.nlm.nih.gov/40067938/Sita Arjune, Katharina Lettenmeier, Polina Todorova...
https://pubmed.ncbi.nlm.nih.gov/39046800/Fabian Woestmann, Sebastian Strubl, Fedja Farowski...
https://pubmed.ncbi.nlm.nih.gov/40459942/University of Cologne
Lead Sponsor